New Analyses Suggest Favorable Results for STELARA ® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn’s Disease and Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately to severely acti...
Source: Johnson and Johnson - October 25, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Janssen Submits Application Seeking U.S. FDA Approval of STELARA ® (ustekinumab) for the Treatment of Pediatric Patients With Juvenile Psoriatic Arthritis
HORSHAM, PENNSYLVANIA, October 8, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking expanded approval of STELARA® (ustekinumab) to treat pediatric patients ages 5 years and older with juvenile psoriatic arthritis (jPsA).The filing is supported by extrapolation of data from nine studies across both adult trials in active PsA and adult and pediatric studies in moderate to severe plaque psoriasis, totaling 3,997 patients evaluated across these closely associated dis...
Source: Johnson and Johnson - October 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
New Analysis Presented by Janssen at United European Gastroenterology Week (UEGW) Demonstrates Long-Term Safety Profile for STELARA ® (ustekinumab) in Older Patients Across Approved Indications
SPRING HOUSE, PENNSYLVANIA, October 4, 2021 – Today, the Janssen Pharmaceutical Companies of Johnson & Johnson announced a new analysis of STELARA® (ustekinumab) pooled safety data from 13 clinical studies across approved indications, showing rates of key safety events among adults 60 years and older treated with STELARA for up to five yearsa were similar to rates observed with placebo during the control phase of these trials.1,b Approved indications included adults with moderately to severely active Crohn’s disease (CD), moderately to severely active ulcerative colitis (UC), moderate to severe plaque psoriasis (P...
Source: Johnson and Johnson - October 4, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
South Africa: UCT's Dr Virginie Rozot Awarded Wellcome Leap Grant for TB Research
[UCT] The University of Cape Town's (UCT) Dr Virginie Rozot, a research officer at the South African Tuberculosis Vaccine Initiative (SATVI), has been awarded a multi?year contract as part of Wellcome Leap's Delta Tissue (?T) programme. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - August 31, 2021 Category: African Health Source Type: news
Why Is the TB Vaccine Not Given in the US
Why Is the TB Vaccine Not Given in the U.S.? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - August 30, 2021 Category: General Medicine Source Type: news
Could a TB Vaccine Protect the Elderly From Severe COVID?
THURSDAY, Aug. 5, 2021 -- Scientists suspect that a century-old tuberculosis vaccine might be able to protect older adults against the worst ravages of COVID-19.
The Bacillus Calmette-Guérin (BCG) vaccine was first used in 1921, and is on... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - August 5, 2021 Category: General Medicine Source Type: news
Could a TB Vaccine Protect the Elderly From Severe COVID?
Title: Could a TB Vaccine Protect the Elderly From Severe COVID?Category: Health NewsCreated: 8/5/2021 12:00:00 AMLast Editorial Review: 8/5/2021 12:00:00 AM (Source: MedicineNet Senior Health General)
Source: MedicineNet Senior Health General - August 5, 2021 Category: Geriatrics Source Type: news
Africa: Investing in New TB Vaccines - It's Time to End the Century-Long Wait!
[WHO] Dear colleagues, partners and friends, (Source: AllAfrica News: Tuberculosis)
Source: AllAfrica News: Tuberculosis - July 26, 2021 Category: Infectious Diseases Source Type: news
Africa: TB Prevention Has Relied On the Same Vaccine for 100 Years. It's Time for Something New
[The Conversation Africa] TB is one of the oldest infectious diseases in recorded history. Most of the people who are ill with TB live in low- and middle-income countries where this disease is one of the leading causes of death. This is particularly distressing given the fact that TB is preventable, treatable and curable. But there's currently only one vaccine approved against TB. And it is 100 years old. The first dose of the Bacille Calmette-Gu érin (BCG) vaccine was administered on July 18 1921. The Conversation Africa's I (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - July 22, 2021 Category: African Health Source Type: news
Nigeria: Health Experts Seek More Effective, Affordable Vaccines to Tackle Tuberculosis
[Premium Times] Global health experts seek improvement of the 100-year-old BCG vaccine. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - July 16, 2021 Category: African Health Source Type: news
STELARA ® (ustekinumab) Demonstrated Sustained Symptomatic and Corticosteroid-Free Remission Rates in Adults with Moderately to Severely Active Ulcerative Colitis at Nearly Three Years in Long-Term Extension of Phase 3 Trial
SPRING HOUSE, PENNSYLVANIA, July 9, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new three-year data from the long-term extension (LTE) of the STELARA® (ustekinumab) Phase 3 UNIFI study. The data demonstrated the majority (55.2 percent) of adult patients with moderately to severely active ulcerative colitis (UC) who initially responded to treatment with STELARA sustained symptomatic remissiona rates at nearly three years (week 152).1 Furthermore, a majority (96.4 percent) of the patients in symptomatic remissiona at week 152 were corticosteroid-free. These data are being presented...
Source: Johnson and Johnson - July 9, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Infographic: TB Vaccines in the Pipeline Take Varied Approaches
More than a dozen vaccines for tuberculosis are currently being tested in clinical trials. Some use whole bacteria as BCG does, while others deliver protein subunits or genetic material carried by... (Source: The Scientist)
Source: The Scientist - July 1, 2021 Category: Science Tags: Infographics Magazine Issue Source Type: news
Further hope for BCG vaccine in stemming type 1 diabetes
(Massachusetts General Hospital) At the recent 2021 Annual Scientific Sessions of the American Diabetes Association, researchers from Massachusetts General Hospital (MGH) presented positive updates on their trials of the bacillus Calmette-Gu é rin (BCG) vaccine to safely and significantly lower blood sugars. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 25, 2021 Category: International Medicine & Public Health Source Type: news
MCRI's BCG vaccine trial joins global race to better understand COVID-19 variants
(Murdoch Childrens Research Institute) An Australian-led study will investigate whether it's possible to predict who remains susceptible to SARS-CoV-2 variants after having COVID-19 or receiving a COVID-19-specific vaccine. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - June 8, 2021 Category: Infectious Diseases Source Type: news
Janssen Presents Results of First Head-to-Head Study of Biologic Therapies in Patients with Moderate to Severe Crohn ’s Disease
SPRING HOUSE, PENNSYLVANIA, May 23, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced efficacy and safety data for STELARA® (ustekinumab) in Crohn’s disease (CD) and ulcerative colitis (UC),1-4including data from the SEAVUE study, the first head-to-head study of biologic therapies in patients with CD, presented in a Clinical Science Late-Breaking Abstract Plenary session.1 SEAVUE data showed treatment with STELARA demonstrated high rates of clinical remission, corticosteroid-free remission, clinical response and endoscopic response through one year in biologic-naïve patients with mo...
Source: Johnson and Johnson - May 24, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
